Delphine Le Louet
Stock Analyst at Bernstein
(0.50)
# 4,376
Out of 5,099 analysts
182
Total ratings
43.4%
Success rate
-5.4%
Average return
Main Sectors:
Stocks Rated by Delphine Le Louet
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ETR: GXI Gerresheimer AG | Reiterated: Hold | €28.70 | €32.20 | -10.87% | 16 | Nov 2, 2026 | |
| EPA: ERF Eurofins Scientific SE | Downgraded: Hold | €53.80 → €73.90 | €87.24 | -15.29% | 8 | Sep 29, 2026 | |
| AMS: LKFT Lakefront Biotherapeutics NV | Reiterated: Hold | €27.90 | €28.72 | -2.86% | 3 | Sep 1, 2026 | |
| ETR: SRT3 Sartorius Aktiengesellschaft | Reiterated: Buy | €284.00 → €273.00 | €292.70 | -6.73% | 22 | Jul 30, 2026 | |
| EPA: DIM Sartorius Stedim Biotech S.A. | Reiterated: Buy | €234.00 → €230.00 | €223.40 | +2.95% | 15 | Jul 28, 2026 | |
| SWX: TECN Tecan Group AG | Upgraded: Hold | CHF 165.20 → CHF 156.00 | CHF 246.80 | -36.79% | 2 | Jan 16, 2026 | |
| STO: GETI.B Getinge AB (publ) | Initiated Coverage: Hold | kr 228.00 | kr 272.30 | n/a | 1 | Jun 17, 2025 | |
| EPA: DBV DBV Technologies S.A. | Reiterated: Buy | €5.70 → €3.03 | €1.79 | n/a | 10 | Mar 17, 2024 | |
| SWX: ALC Alcon Inc. | Reiterated: Hold | CHF 77.60 → CHF 72.20 | CHF 59.84 | n/a | 16 | Feb 29, 2024 | |
| EPA: IPN Ipsen S.A. | Reiterated: Buy | €142.00 → €150.40 | €153.20 | n/a | 14 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €20.30 → €13.60 | €3.55 | n/a | 9 | Dec 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €57.00 → €57.10 | €43.35 | n/a | 7 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | €20.10 → €18.95 | €25.70 | n/a | 12 | Oct 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | €186.40 → €189.80 | €184.25 | n/a | 19 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | €103.00 → €101.00 | €94.75 | n/a | 15 | Sep 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $28.46 | n/a | 2 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | €579.00 → €612.00 | €229.00 | n/a | 6 | Jan 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | $12 | $10.11 | n/a | 4 | May 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | $142 | $103.03 | n/a | 1 | Oct 8, 2020 |
Gerresheimer AG
Nov 2, 2026
Reiterated: Hold
Price Target: €28.70
Current: €32.20
Upside: -10.87%
Eurofins Scientific SE
Sep 29, 2026
Downgraded: Hold
Price Target: €53.80 → €73.90
Current: €87.24
Upside: -15.29%
Lakefront Biotherapeutics NV
Sep 1, 2026
Reiterated: Hold
Price Target: €27.90
Current: €28.72
Upside: -2.86%
Sartorius Aktiengesellschaft
Jul 30, 2026
Reiterated: Buy
Price Target: €284.00 → €273.00
Current: €292.70
Upside: -6.73%
Sartorius Stedim Biotech S.A.
Jul 28, 2026
Reiterated: Buy
Price Target: €234.00 → €230.00
Current: €223.40
Upside: +2.95%
Tecan Group AG
Jan 16, 2026
Upgraded: Hold
Price Target: CHF 165.20 → CHF 156.00
Current: CHF 246.80
Upside: -36.79%
Getinge AB (publ)
Jun 17, 2025
Initiated Coverage: Hold
Price Target: kr 228.00
Current: kr 272.30
Upside: n/a
DBV Technologies S.A.
Mar 17, 2024
Reiterated: Buy
Price Target: €5.70 → €3.03
Current: €1.79
Upside: n/a
Alcon Inc.
Feb 29, 2024
Reiterated: Hold
Price Target: CHF 77.60 → CHF 72.20
Current: CHF 59.84
Upside: n/a
Ipsen S.A.
Jan 3, 2024
Reiterated: Buy
Price Target: €142.00 → €150.40
Current: €153.20
Upside: n/a
Dec 22, 2023
Reiterated: Buy
Price Target: €20.30 → €13.60
Current: €3.55
Upside: n/a
Nov 13, 2023
Reiterated: Buy
Price Target: €57.00 → €57.10
Current: €43.35
Upside: n/a
Oct 24, 2023
Reiterated: Hold
Price Target: €20.10 → €18.95
Current: €25.70
Upside: n/a
Oct 20, 2023
Upgraded: Buy
Price Target: €186.40 → €189.80
Current: €184.25
Upside: n/a
Sep 29, 2023
Reiterated: Hold
Price Target: €103.00 → €101.00
Current: €94.75
Upside: n/a
Oct 13, 2022
Downgraded: Hold
Price Target: n/a
Current: $28.46
Upside: n/a
Jan 28, 2022
Upgraded: Buy
Price Target: €579.00 → €612.00
Current: €229.00
Upside: n/a
May 4, 2021
Upgraded: Hold
Price Target: $12
Current: $10.11
Upside: n/a
Oct 8, 2020
Upgraded: Hold
Price Target: $142
Current: $103.03
Upside: n/a